Targeting Podoplanin for the Treatment of Osteosarcoma.
Ai TakemotoSatoshi TakagiTakao UkajiNobuhiko GyobuMamoru KakinoMiho TakamiAsami KobayashiMarie LebelTokuichi KawaguchiMinoru SugawaraKazue Tsuji-TakayamaKenji IchiharaYuki FunauchiKeisuke AeSeiichi MatsumotoYoshiya SugiuraKengo TakeuchiTetsuo NodaRyohei KatayamaNaoya FujitaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Targeting PDPN with a neutralizing antibody against PDPN-CLEC-2 without antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity is a novel therapeutic strategy for PDPN-positive osteosarcoma.